Fumarate induces vesicular release of mtDNA to drive innate immunity.
Zecchini V, Paupe V, Herranz-Montoya I, Janssen J, Wortel IMN, Morris JL, Ferguson A, Chowdury SR, Segarra-Mondejar M, Costa ASH, Pereira GC, Tronci L, Young T, Nikitopoulou E, Yang M, Bihary D, Caicci F, Nagashima S, Speed A, Bokea K, Baig Z, Samarajiwa S, Tran M, Mitchell T, Johnson M, Prudent J, Frezza C. · 2023
Read Fumarate induces vesicular release of mtDNA to drive innate immunity. by Zecchini V, Paupe V, Herranz-Montoya I, Janssen J, Wortel IMN, Morris JL, Ferguson A, Chowdury SR, Segarra-Mondejar M, Costa ASH, Pereira GC, Tronci L, Young T, Nikitopoulou E, Yang M, Bihary D, Caicci F, Nagashima S, Speed A, Bokea K, Baig Z, Samarajiwa S, Tran M, Mitchell T, Johnson M, Prudent J, Frezza C. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10017517.txt.
Introduction
Zecchini and a large team report that a cell chemical called fumarate can trigger the release of mitochondrial DNA and switch on immune defenses, in a 2023 study. Mutations that block the breakdown of fumarate cause a rare inherited condition with kidney cancer. Fumarate then builds up inside cells to high levels.
The team traced how that buildup pushes DNA out of the cell's powerhouses in tiny packages. The loose DNA acts as an alarm signal to the immune system. The finding links cell fuel use to immune activity in a new way.
Catalog record
| CREATOR | Zecchini V, Paupe V, Herranz-Montoya I, Janssen J, Wortel IMN, Morris JL, Ferguson A, Chowdury SR, Segarra-Mondejar M, Costa ASH, Pereira GC, Tronci L, Young T, Nikitopoulou E, Yang M, Bihary D, Caicci F, Nagashima S, Speed A, Bokea K, Baig Z, Samarajiwa S, Tran M, Mitchell T, Johnson M, Prudent J, Frezza C. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Fumarate induces vesicular release of mtDNA to drive innate immunity By Vincent Zecchini, Vincent Paupe, Irene Herranz-Montoya, Joëlle Janssen, Inge M. N. Wortel, Jordan L. Morris, Ashley Ferguson, Suvagata Roy Chowdury, Marc Segarra-Mondejar, Ana S. H. Costa, Gonçalo C. Pereira, Laura Tronci Published in: Nature DOI: 10.1038/s41586-023-05770-w ABSTRACT Mutations in fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma1. Loss of FH in the kidney elicits several oncogenic signalling cascades through the accumulation of the oncometabolite fumarate2. However, although the long-term consequences of FH loss have been described, the acute response has not so far been investigated. Here we generated an inducible mouse model to study the chronology of FH loss in the kidney. We show that loss of FH leads to early alterations of mitochondrial morphology and the release of mitochondrial DNA (mtDNA) into the cytosol, where it triggers the activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING)–TANK-binding kinase 1 (TBK1) pathway and stimulates an inflammatory response that is also partially dependent on retinoic-acid-inducible gene I (RIG-I). Mechanistically, we show that this phenotype is mediated by fumarate and occurs selectively through mitochondrial-derived vesicles in a manner that depends on sorting nexin 9 (SNX9). These results reveal that increased levels of intracellular fumarate induce a remodelling of the mitochondrial network and the generation of mitochondrial-derived vesicles, which allows the release of mtDNAin the cytosol and subsequent activation of the innate immune response. MAIN Fumarate hydratase (FH), a metabolic enzyme of the tricarboxylic acid (TCA) cycle that catalyses the reversible conversion of fumarate to malate, has been identified as a bona fide tumour suppressor2. Loss of FH predisposes to hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a syndrome that is characterized by an aggressive form of kidney cancer. A hallmark of both FH-deficient cells and tumours is the aberrant accumulation of fumarate3, which has been shown to drive malignant transformation and tumour progression through the activation of a series of oncogenic cascades2. However, when analysed in tumours or other cellular models, all of these signalling cascades are already simultaneously activated and are likely to be intertwined, which makes it difficult to elucidate their hierarchy, cross-talk and causal contribution to the disease. Here we generated an inducible transgenic mouse model to investigate the chronology of the loss of Fh1, the mouse orthologue of human FH, in the adult kidney. By crossing a previously generated Fh1fl/fl strain4 with mice that contain a ubiquitously expressed tamoxifen-inducible Cre recombinase at the Rosa26 locus5, we obtained a tamoxifen-inducible Fh1fl/fl strain (Fig. 1a). Treating Fh1fl/fl mice with tamoxifen resulted in the efficient excision of Fh1 exons 3 and 4 (hereafter termed Fh1−/−), compared to the control strain (Fh1+/+) (Fig. 1b and Extended Data Fig. 1a,b). Loss of FH causes profound metabolic changes, including the aberrant intracellular accumulation of argininosuccinate6 and of products of the reaction by which fumarate is added to the thiol groups of free cysteine and to the thiol groups of proteins7, generating S-(2-succinyl)cysteine (2SC) and succinated proteins, respectively. Both reactions buffer the excess of fumarate production, which eventually occurs when these and other buffering systems have reached capacity (Extended Data Fig. 1c). We observed an early increase of 2SC at day 5, followed by an increase of all these metabolic markers, including fumarate, at day 10 in Fh1−/− kidneys (Fig. 1c). Macroscopically, there were no gross morphological differences between wild-type and Fh1-deficient kidneys (Fig. 1d).Fig. 1Loss of Fh1 in the adult mouse kidney triggers an early inflammatory response.a, Genome-editing strategy for generating inducible Fh1 knockout alleles. Rosa26-Cre-ERT2 mice carry the tamoxifen-responsive Cre recombinase transgene downstream of the Rosa26 promoter5. Fh1fl/fl mice13 contain two loxP sites flanking Fh1 exons 3 and 4. Intraperitoneal injection of tamoxifen in the adult mouse induces the nuclear translocation of the ubiquitously expressed Cre–ERT2 fusion protein, resulting in the excision of the genomic fragment located between the loxP sites to generate Fh1 null alleles (Fh1−/−). Mice of about 90 days of age are treated with tamoxifen and the kidneys are collected for analysis at day 5 and day 10 after injection. b, Fh1 mRNA expression levels in wild-type control (Fh1+/+) and Fh1-deficient (Fh1−/−) adult mouse kidneys, measured by qRT–PCR. c, Metabolite abundance (normalized peak ion intensity, arbitrary units (AU)) in Fh1+/+ and Fh1−/− adult mouse kidney measured by liquid chromatography–mass spectrometry (LC–MS). d, Haematoxylin and eosin (H&E) staining of Fh1+/+ and Fh1−/− adult mouse kidney at day 10 after induction. Scale bars, 100 μm. e, Volcano plots of the GSEA, highlighting the differentially regulated pathways in Fh1−/− versus Fh1+/+ kidney tissue at day 10 after induction. FDR, false discovery rate; NES, normalized enrichment score. f, Heat map showing upregulated inflammation-related genes in Fh1−/− versus Fh1+/+ kidney tissue at day 5 and day 10 after induction (white cells mean no difference between the two groups). g, Expression levels of ISGs in Fh1−/− versus Fh1+/+ kidney tissue at day 5 and day 10 after induction, measured by qRT–PCR. Data are mean ± s.e.m. b,c,g, n = minimum 8 mice in each group, Student’s t-test corrected for multiple comparisons with the Holm–Sidak method.Source data LOSS OF FH1 TRIGGERS AN INFLAMMATORY RESPONSE To investigate the acute response to the loss of Fh1, we performed a transcriptomic analysis of the mouse kidney (Fig. 1a and Supplementary Table 1). The most prevalent altered biological processes were linked to pathways that are involved in inflammation and the innate immune response (Fig. 1e and Supplementary Tables 2 and 3). We also observed an increase in interferon-stimulated genes (ISGs), with Ifi202b being the most upregulated transcript (Fig. 1f, Extended Data Fig. 1d and Supplementary Table 1), and found that this was associated with an upregulation of pro-inflammatory cytokines and chemokines (Fig. 1f,g). Deconvolution of the transcriptomics data revealed that immune cells contributed to a low fraction of the signal that was observed (Extended Data Fig. 1e). In addition, although we confirmed the presence of succinated proteins, there were no changes in the expression of CD14 (a marker of immune cells) in Fh1−/− kidney tissue (Extended Data Fig. 1f), ruling out infiltrating immune cells as the cause of the immune signature observed. To confirm the cell-autonomous nature of the phenotype, we generated epithelial cell lines from Fh1fl/fl mouse kidneys8, hereafter referred to as inducible Fh1 clones 29 or 33 (iFh1−/−CL29 or iFh1−/−CL33 after recombination and Fh1 loss) (Extended Data Fig. 2a). Treating iFh1fl/flCL29 and iFh1fl/flCL33 cells with 4-hydroxytamoxifen (4-OHT) resulted in a time-dependent decrease in the mRNA and protein levels of Fh1, accompanied by reductions in the mitochondrial membrane potential and respiration; it also induced an early increase in the metabolic markers 2SC and argininosuccinate, followed by the accumulation of fumarate, and transcriptional hallmarks of Fh1 loss (Fig. 2a,b, Extended Data Fig. 2b–d and Supplementary Fig. 1a–d).Fig. 2Activation of the cGAS–STING pathway in Fh1-deficient cells is triggered by cytosolic mtDNA.a, qRT–PCR (top) and immunoblots (bottom) showing the expression levels of Fh1 (top) or FH protein (bottom) in inducible iFh1 epithelial kidney cell lines clones 29 (iFh1fl/flCL29) that were not treated (NT) or were treated with either vehicle (ethanol; EtOH) or 4-OHT (iFh1−/−CL29) for the indicated period of time. n = 5 independent experiments. b, Relative abundance (normalized peak ion intensity) of fumarate (left), 2SC (middle) and